02 May 2022 | Features
Developing scalable cell replacement therapies for the world
Domain- Biotech (Therapeutics)
Founders- Dr Jogin Desai, Dr Rajani Battu, Dr Dhruv Sareen and Dr Rajarshi Pal
Total team strength- 9
Total funds raised- Rs 30.5 crore
Investors- Endiya partners, Kotak Private Equity and others
Revenue generated since inception- Pre-revenue stage
"Biotech investments in India are hard to come by through the VC community. Also, the ability to think of science in product development vs academic research is lacking.
I am very bullish about the growth of the biotech sector, which I firmly believe will do what the IT sector did for the Indian economy 20 years ago. Developed countries spend about 2.5 % of their GDP, while India has spent less than 1.5% of their GDP in the biotech sector. India needs to invest in science for the next 20 years at over 2.5 % of GDP. Indian Pharma companies should leverage this opportunity and invest in innovative startups which align with their core philosophy, as Biotech investments provide better returns than tech investments."
- Dr Jogin Desai, Founder & Chief Executive Officer, Eyestem Research, Bengaluru